This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Cabergoline Effect on Blood Sugar in Type 2 Diabetics

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2011 by Haleh Rokni Yazdi, Mashhad University of Medical Sciences.
Recruitment status was:  Not yet recruiting
Sponsor:
Information provided by (Responsible Party):
Haleh Rokni Yazdi, Mashhad University of Medical Sciences
ClinicalTrials.gov Identifier:
NCT01459601
First received: October 24, 2011
Last updated: NA
Last verified: October 2011
History: No changes posted
  Purpose
Diabetic patients with poorly control blood sugar are prescribed cabergoline for 1 months and their blood glucose is evaluated.

Condition Intervention
Diabetes Type 2 Drug: Cabergoline

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single Blind (Participant)
Primary Purpose: Treatment
Official Title: Cabergoline Effects on Blood Sugar Control in Type 2 Diabetics

Resource links provided by NLM:


Further study details as provided by Haleh Rokni Yazdi, Mashhad University of Medical Sciences:

Primary Outcome Measures:
  • FBS (fasting blood sugar) [ Time Frame: 30days ]

Secondary Outcome Measures:
  • HbA1C [ Time Frame: 30days ]

Estimated Enrollment: 10
Study Start Date: January 2012
Estimated Study Completion Date: February 2012
Estimated Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Cabergoline
    0,5mg per week
    Other Name: Dastinex
  Eligibility

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 2 diabetes
  • HbA1C>7

Exclusion Criteria:

  • HbA1C>10
  • Psychiatric disorders
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: Haleh Rokni Yazdi, assisstant professor, Mashhad University of Medical Sciences
ClinicalTrials.gov Identifier: NCT01459601     History of Changes
Other Study ID Numbers: CabergolinDM
Study First Received: October 24, 2011
Last Updated: October 24, 2011

Keywords provided by Haleh Rokni Yazdi, Mashhad University of Medical Sciences:
diabetes mellitus
FBS
HbA1C
Cabergoline

Additional relevant MeSH terms:
Diabetes Mellitus, Type 2
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Cabergoline
Antineoplastic Agents
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on June 28, 2017